AMPHASTAR PHARMACEUTICALS INC (AMPH)
Health Care · Generic and specialty injectable pharmaceuticals / inhalation drugs · NASDAQ
Amphastar manufactures technically complex generic and proprietary injectable, inhalation, and intranasal drugs with high barriers to entry, leveraging proprietary formulation and manufacturing capabilities to compete in high-margin, supply-constrained markets.
What AMPHASTAR PHARMACEUTICALS INC does
Amphastar is a biopharmaceutical company that develops, manufactures, and commercializes technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as active pharmaceutical ingredients (APIs). The company currently markets over 25 prescription pharmaceutical products and one over-the-counter product (Primatene MIST®), with major products including BAQSIMI® (nasally administered glucagon for severe hypoglycemia), albuterol sulfate inhalation aerosol, iron sucrose injection, and teriparatide injection. Amphastar has built technological capabilities in peptide synthesis, complex molecule characterization, sustained-release technology, and manufacturing of various dosage formulations.
Themes: ["Generic injectables","Proprietary inhalation products","Glucagon / severe hypoglycemia treatment","Biosimilars / biological drug products","Drug delivery technologies","Active pharmaceutical ingredients (APIs)","High-barrier-to-entry formulations","Respiratory / asthma / COPD treatments"]
Fundamentals
- Price$19.02 as of 2026-07-09 close
- Market cap$832M as of 2026-07-10
- 1-year return-15.2% as of 2026-07-09 close
- P/E10.51 as of 2026-07-10
- Net margin+11.0% as of 2026-07-10
- Gross margin+47.3% as of 2026-07-10
- ROE+10.2% as of 2026-07-10
- Debt / equity0.79 as of 2026-07-10
- Revenue growth (YoY)-1.4% as of 2026-07-10
- Revenue CAGR (3y)+13.0% SEC XBRL
- Beta0.91 as of 2026-07-10
Key risks (from latest filing)
["Supply chain concentration risk from single-source suppliers and reliance on third-party manufacturers for raw materials and APIs","Regulatory and FDA approval risks for product candidates and manufacturing operations, including timing and approval of pending ANDAs and biosimilar insulin candidates","Pricing pressure and reimbursement challenges from healthcare reforms, drug price controls, and competitive generic market dynamics"]
Competitors & peers
- Sandoz (specialty generics and injectables)
- Baxter International (injectable pharmaceuticals)
- Hikma Pharmaceuticals (generic injectables)
- Endo Pharmaceuticals (specialty injectables)
- West Pharmaceutical Services (injectable delivery systems)
- Hospira / Pfizer Sterile Injectables (injectable generics)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.